<DOC>
	<DOCNO>NCT01247922</DOCNO>
	<brief_summary>Participants assign oral etoposide treatment arm protocol OSI-774-205 either progress study discontinue due unacceptable toxicity relate etoposide allow participate study assess safety profile single-agent erlotinib participant recurrent refractory pediatric ependymoma .</brief_summary>
	<brief_title>Single-agent Erlotinib Patients Previously Treated With Oral Etoposide Protocol OSI-774-205</brief_title>
	<detailed_description>The protocol-specified futility criterion meet second interim analysis date 15 Aug 2012 OSI-774-205 . Per Data Monitoring Committee 's recommendation FDA 's agreement , enrollment patient study Study OSI-774-206 permanently close .</detailed_description>
	<mesh_term>Ependymoma</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Patients must enrol OSI774205 , randomize oral etoposide either progress study discontinue due unacceptable toxicity relate etoposide Performance status : Lansky ≥ 50 % patient ≤ 10 year age young Karnofsky ≥ 50 % patient great 10 year age Patients must recover acute toxicity prior anticancer treatment Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) age , serum glutamic pyruvic transaminase ( SGPT ) ALT ≤ 3 x ULN Serum creatinine base age OR Creatinine Clearance/Glomerular Filtration Rate ( GFR ) ≥ 70 mL/min/m2 Patients must neurologically stable least 7 day registration Patients , male female , reproductive potential must agree practice effective contraceptive measure duration study drug therapy least 90 day completion study drug therapy Patients must able take erlotinib orally Taking strong/moderate CYP3A4 CYP1A2 inhibitors/inducers ≤ 14 day registration Have receive chemotherapy immunotherapy treat ependymoma discontinuation OSI774205 Taking proton pump inhibitor ≤ 14 day registration Participating another investigational drug trial study Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Pediatric Ependymoma</keyword>
	<keyword>Ependymoma</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Tarceva</keyword>
</DOC>